{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:14:59Z","timestamp":1779923699165,"version":"3.53.1"},"reference-count":21,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000027","name":"NIAAA","doi-asserted-by":"crossref","award":["1U24AA020794"],"award-info":[{"award-number":["1U24AA020794"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000027","name":"NIAAA","doi-asserted-by":"crossref","award":["1U01AA020790"],"award-info":[{"award-number":["1U01AA020790"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000027","name":"NIAAA","doi-asserted-by":"crossref","award":["U24AA022001"],"award-info":[{"award-number":["U24AA022001"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"crossref","award":["2P30MH062294"],"award-info":[{"award-number":["2P30MH062294"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"crossref","award":["2 U01-A1069918"],"award-info":[{"award-number":["2 U01-A1069918"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIDA","award":["R01DA035616"],"award-info":[{"award-number":["R01DA035616"]}]},{"DOI":"10.13039\/100000133","name":"AHRQ","doi-asserted-by":"crossref","award":["R01HS018372"],"award-info":[{"award-number":["R01HS018372"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NCI","award":["R01 CA173754"],"award-info":[{"award-number":["R01 CA173754"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Effectiveness, safety and tolerability of boceprevir (<jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>) and telaprevir (<jats:styled-content style=\"fixed-case\">TPV<\/jats:styled-content>) in actual clinical settings remain unknown. We determined rates of sustained virologic response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>) and haematologic adverse effects among persons treated with <jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>\u2010 or <jats:styled-content style=\"fixed-case\">TPV<\/jats:styled-content>\u2010containing regimens, compared with pegylated interferon\/ribavirin (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>). Using an established cohort of hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>)\u2010infected persons, Electronically Retrieved Cohort of HCV Infected Veterans (<jats:styled-content style=\"fixed-case\">ERCHIVES<\/jats:styled-content>), we identified those treated with a <jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>\u2010 or <jats:styled-content style=\"fixed-case\">TPV<\/jats:styled-content>\u2010containing regimen and <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1\u2010infected controls treated with <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>. We excluded those with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> coinfection and missing <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> values to determine <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>. Primary endpoints were <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> (undetectable <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> \u226512\u00a0weeks after treatment completion) and haematologic toxicity (grade 3\/4 anaemia, neutropenia and thrombocytopenia). We evaluated 2288 persons on <jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>\u2010, 409 on <jats:styled-content style=\"fixed-case\">TPV<\/jats:styled-content>\u2010containing regimen and 6308 on <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>. Among these groups, respectively, 31%, 43% and 9% were treatment\u2010experienced; 17%, 37% and 14% had baseline cirrhosis; 63%, 54% and 48% were genotype 1a. <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rates among noncirrhotics were as follows: treatment na\u00efve: 65% (<jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>), 67% (<jats:styled-content style=\"fixed-case\">TPV<\/jats:styled-content>) and 31% (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>); treatment experienced: 57% (<jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>), 54% (<jats:styled-content style=\"fixed-case\">TPV<\/jats:styled-content>) and 13% (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>); (<jats:italic>P\u2010<\/jats:italic>value not significant for <jats:styled-content style=\"fixed-case\">BOC <\/jats:styled-content><jats:italic>vs <\/jats:italic><jats:styled-content style=\"fixed-case\">TPV<\/jats:styled-content>;<jats:italic> P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.0001 for <jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">TPV <\/jats:styled-content><jats:italic>vs <\/jats:italic><jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>). Haematologic toxicities among <jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>\u2010, <jats:styled-content style=\"fixed-case\">TPV<\/jats:styled-content>\u2010 and <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>\u2010treated groups were as follows: grade 3\/4 anaemia 7%, 11% and 3%; grade 4 thrombocytopenia 2.2%, 5.4% and 1.7%; grade 4 neutropenia 8.2%, 5.6% and 3.4%. <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rates are higher and closer to those reported in pivotal clinical trials among <jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>\u2010 and <jats:styled-content style=\"fixed-case\">TPV<\/jats:styled-content>\u2010treated persons compared with <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>\u2010treated persons. Haematologic adverse events are frequent, but severe toxicity is uncommon.<\/jats:p>","DOI":"10.1111\/jvh.12375","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T09:04:42Z","timestamp":1418979882000},"page":"691-700","source":"Crossref","is-referenced-by-count":14,"title":["Virologic response and haematologic toxicity of boceprevir\u2010 and telaprevir\u2010containing regimens in actual clinical settings"],"prefix":"10.1111","volume":"22","author":[{"given":"A. A.","family":"Butt","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Medicine Pittsburgh PA USA"},{"name":"VA Pittsburgh Healthcare System Pittsburgh PA USA"},{"name":"Hamad Medical Corporation Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Yan","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. S.","family":"Shaikh","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine Pittsburgh PA USA"},{"name":"VA Pittsburgh Healthcare System Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Freiberg","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"V.","family":"Lo Re","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Justice","sequence":"additional","affiliation":[{"name":"Veterans Affairs Healthcare System West Haven CT USA"},{"name":"Yale University School of Medicine New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. E.","family":"Sherman","sequence":"additional","affiliation":[{"name":"University of Cincinnati Medical Center Cincinnati OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908014"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60247-0"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.004"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-014-0949-8"},{"key":"e_1_2_9_9_1","unstructured":"AASLD IDSA IAS\u2010USA.Recommendations for testing managing and treating hepatitis C. Available at:http:\/\/www.hcvguidelines.org(accessed 24 April 2014) 2014."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27151"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00885.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/599371"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23000"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02156.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.09.023"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12107"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.01.023"},{"key":"e_1_2_9_18_1","volume-title":"Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System","author":"World Health Organization","year":"2011"},{"key":"e_1_2_9_19_1","article-title":"Liver fibrosis progression in hepatitis C virus infection after seroconversion","author":"Butt AA","year":"2014","journal-title":"JAMA Intern Med"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1001-25"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12546"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir774"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12375","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12375","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T08:33:44Z","timestamp":1696235624000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/jvh.12375"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12375","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,18]]}}}